R&D Investment

R&D Investment

Investing in what comes next

R&D Investment

Shenzhen Dake Medical Technology Co., Ltd. was incorporated in March 2022 and covers an area of 2,000 m². It has a 350 m² Class 100,000 cleanroom and four Class 10,000 cleanrooms.

Dake attaches great importance to R&D investment, which accounts for over 45%. In both instruments and reagents, our R&D is led by senior industry experts with more than 15 years of experience. To date, we have completed independent development of chemiluminescence diagnostic instruments with more than 70 matching reagents, and HbA1c analyzers with matching reagents.

Within the next three years, we will continue to deepen our R&D and develop and register no fewer than 20 chemiluminescence assay reagent products, along with high-performance HbA1c instruments and matching reagents.